H.C. Wainwright analyst Vernon Bernardino reiterated a Buy rating on NRX Pharmaceuticals (NRXP – Research Report) today and set a price target of $2.00. The company’s shares closed yesterday at $0.67.
Bernardino covers the Healthcare sector, focusing on stocks such as Gamida Cell, Cassava Sciences, and GeoVax Labs. According to TipRanks, Bernardino has an average return of 13.8% and a 29.80% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for NRX Pharmaceuticals with a $3.25 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $1.54 and a one-year low of $0.49. Currently, NRX Pharmaceuticals has an average volume of 146.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Big Rock Partners Acquisition Corp. is a blank check company, which was formed for the purpose of entering into a merger, stock exchange, asset acquisition, stock purchase, reorganization, recapitalization or other similar business combination with one or more businesses or entities. It focuses on identifying a prospective target business in the senior housing and care industry in the United States. The firm’s care segments are commonly divided into four categories: Independent Living; Assisted Living; Memory Care and Nursing Care. The company was founded on September 18, 2017 and is headquartered in Delray Beach, FL.
Read More on NRXP:
- NRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
- NRXP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update
- Nrx Pharmaceuticals, Inc. (NRXP) Q4 Earnings Cheat Sheet
- NRx Pharmaceuticals announces DSMB recommendation to continue NRX-101 enrollment
